<DOC>
	<DOCNO>NCT01028391</DOCNO>
	<brief_summary>A 30-week extension 24-week study assess hemoglobin A1c ( HbA1c ) - fast plasma glucose ( FPG ) -lowering efficacy combination sitagliptin pioglitazone patient type 2 diabetes mellitus ( T2DM ) inadequate glycemic control .</brief_summary>
	<brief_title>30-Week Extension Initial Combination Study ( 24 Weeks Duration ) Sitagliptin With Pioglitazone ( 0431-064 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients must complete doubleblind base study ( MK043106400 ) ( NCT00397631 ) least 75 % compliance study medication base study treatment period . Women childbearing potential must continue comply protocolspecified contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>